Contineum Therapeutics (CTNM) Non-Current Assets (2023 - 2026)

Contineum Therapeutics' Non-Current Assets history runs 4 years deep, the most recent figure standing at $8.4 million for Q1 2026.

• In Q1 2026, Non-Current Assets rose 36.79% year-over-year to $8.4 million; the TTM figure through Mar 2026 stood at $29.1 million (up 100.34% YoY), while the FY2025 annual figure was $8.7 million, up 35.08% from the prior year.
• Non-Current Assets was $8.4 million for Q1 2026 at Contineum Therapeutics, down from $8.7 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $8.7 million in Q4 2025 to a low of $891000.0 in Q3 2024.
• Historically, Non-Current Assets has averaged $5.0 million across 4 years, with a median of $6.0 million in 2025.
• Biggest YoY gain for Non-Current Assets was 564.42% in 2025; the steepest drop was 35.08% in 2025.
• A 4-year view of Non-Current Assets shows it stood at $2.7 million in 2023, then jumped by 141.01% to $6.5 million in 2024, then surged by 35.08% to $8.7 million in 2025, then declined by 3.9% to $8.4 million in 2026.
• The last three Non-Current Assets figures came in at $8.4 million (Q1 2026), $8.7 million (Q4 2025), and $5.9 million (Q3 2025), per Business Quant data.